» Articles » PMID: 20161770

Alternative Splicing of the Angiogenesis Associated Extra-domain B of Fibronectin Regulates the Accessibility of the B-C Loop of the Type III Repeat 8

Overview
Journal PLoS One
Date 2010 Feb 18
PMID 20161770
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fibronectin (FN) is a multi-domain molecule involved in many cellular processes, including tissue repair, embryogenesis, blood clotting, and cell migration/adhesion. The biological activities of FN are mediated by exposed loops located mainly at the interdomain interfaces that interact with various molecules such as, but not only, integrins. Different FN isoforms arise from the alternative splicing of the pre-mRNA. In malignancies, the splicing pattern of FN pre-mRNA is altered; in particular, the FN isoform containing the extra-domain B (ED-B), a complete FN type III repeat constituted by 91 residues, is undetectable in normal adult tissues, but exhibits a much greater expression in fetal and tumor tissues, and is accumulated around neovasculature during angiogenic processes, thus making ED-B one of the best markers and targets of angiogenesis. The functions of ED-B are still unclear; however, it has been postulated that the insertion of an extra-domain such as ED-B modifies the domain-domain interface and may unmask loops that are otherwise cryptic, thus giving FN new potential activities.

Methodology: We used the mAb C6, which reacts with ED-B containing FN, but not with ED-B-free FN and various recombinant FN fragments containing mutations, to precisely localize the epitopes recognized by the mAb C6.

Conclusion: We formally demonstrated that the inclusion of the alternatively spliced angiogenesis-associated ED-B leads to the unmasking of the FNIII 8 B-C loop that is cryptic in FN molecules lacking ED-B. Thus, the mAb C6, in addition to providing a new reagent for angiogenesis targeting, represents a new tool for the study of the potential biological functions of the B-C loop of the repeat FNIII 8 that is unmasked during angiogenic processes.

Citing Articles

Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.

Saw P, Xu X, Kang B, Lee J, Lee Y, Kim C Theranostics. 2021; 11(2):941-957.

PMID: 33391514 PMC: 7738868. DOI: 10.7150/thno.44948.


Alternatively spliced isoforms reveal a novel type of PTB domain in CCM2 protein.

Jiang X, Padarti A, Qu Y, Sheng S, Abou-Fadel J, Badr A Sci Rep. 2019; 9(1):15808.

PMID: 31676827 PMC: 6825194. DOI: 10.1038/s41598-019-52386-0.


Genetically Programmable Self-Regenerating Bacterial Hydrogels.

Duraj-Thatte A, Dorval Courchesne N, Praveschotinunt P, Rutledge J, Lee Y, Karp J Adv Mater. 2019; 31(40):e1901826.

PMID: 31402514 PMC: 6773506. DOI: 10.1002/adma.201901826.


Targeting Fibronectin for Cancer Imaging and Therapy.

Han Z, Lu Z J Mater Chem B. 2017; 5(4):639-654.

PMID: 29270293 PMC: 5733799. DOI: 10.1039/C6TB02008A.


Fibronectin Mechanobiology Regulates Tumorigenesis.

Wang K, Seo B, Fischbach C, Gourdon D Cell Mol Bioeng. 2016; 9:1-11.

PMID: 26900407 PMC: 4746220. DOI: 10.1007/s12195-015-0417-4.


References
1.
Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale G . Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002; 161(5):1695-700. PMC: 1850782. DOI: 10.1016/S0002-9440(10)64446-X. View

2.
Mariani G, Lasku A, Balza E, Gaggero B, Motta C, Di Luca L . Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer. 1997; 80(12 Suppl):2378-84. DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2378::aid-cncr7>3.3.co;2-0. View

3.
Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P . Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998; 273(34):21769-76. DOI: 10.1074/jbc.273.34.21769. View

4.
Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A . Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer. 1996; 68(3):397-405. DOI: 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4. View

5.
Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A . Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002; 102(1):75-85. DOI: 10.1002/ijc.10662. View